Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study

Kardiol Pol. 2022;80(6):696-698. doi: 10.33963/KP.a2022.0104. Epub 2022 Apr 21.

Authors

Dimitrios Patoulias¹, Maria Toumpourleka², Alexandra Katsimardou³, Ioanna Zografou³, Konstantinos Stavropoulos³, Konstantinos Imprialos³, Asterios Karagiannis³, Michael Doumas³, Christodoulos Papadopoulos²

Affiliations

¹ 2nd Propaedeutic Department of Internal Medicine, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece. [email protected].
² 3rd Department of Cardiology, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ 2nd Propaedeutic Department of Internal Medicine, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.

PMID: 35445742
DOI: 10.33963/KP.a2022.0104

No abstract available

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucose
Humans
Hypoglycemic Agents
Pilot Projects
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Symporters*
Ventricular Function, Right

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Symporters
Sodium
Glucose